GlycoMimetics, Inc. Stock price

Equities

GLYC

US38000Q1022

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
2.8 USD +9.38% Intraday chart for GlycoMimetics, Inc. +9.38% +18.64%
Sales 2023 * - Sales 2024 * - Capitalization 180M
Net income 2023 * -37M Net income 2024 * -41M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-4.65 x
P/E ratio 2024 *
-4.96 x
Employees 39
Yield 2023 *
-
Yield 2024 *
-
Free-Float 97.01%
More Fundamentals * Assessed data
Dynamic Chart
1 day+9.38%
1 week+9.38%
Current month-3.11%
1 month-13.04%
3 months+42.13%
6 months+95.80%
Current year+18.64%
More quotes
1 week
2.50
Extreme 2.5
2.87
1 month
2.50
Extreme 2.5
3.36
Current year
2.20
Extreme 2.2
3.53
1 year
1.11
Extreme 1.11
3.53
3 years
0.51
Extreme 0.51
4.16
5 years
0.51
Extreme 0.51
13.56
10 years
0.51
Extreme 0.51
26.05
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 21-08-05
Founder 64 03-04-03
Director of Finance/CFO 49 10-01-31
Members of the board TitleAgeSince
Director/Board Member 71 16-03-16
Director/Board Member 66 17-06-11
Director/Board Member 59 18-11-27
More insiders
Date Price Change Volume
24-03-18 2.8 +9.37% 468,254
24-03-15 2.56 -1.92% 244,038
24-03-14 2.61 +2.35% 177,965
24-03-13 2.55 -2.67% 424,612
24-03-12 2.62 +2.34% 323,483

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
GlycoMimetics, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of glycomimetic drugs. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer, and infection. Its drug candidates include Uproleselan, GMI-1359, GMI-1687, and Galectin Antagonists. It is developing Uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). Its GMI-1359 targets both E-selectin and a chemokine receptor known as CXCR4. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. The Company is engaged in advancing other preclinical-stage programs, including small-molecule glycomimetic compounds that inhibit the protein galectin-3.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.8 USD
Average target price
7 USD
Spread / Average Target
+150.00%
Consensus
  1. Stock
  2. Equities
  3. Stock GlycoMimetics, Inc. - Nasdaq